Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q1 FY27 results · Apr–Jun 2026
Supriya Lifescience reported revenue from operations of ₹189.75 crore (up 30.8% from Q1 FY26) and net profit of ₹24.04 crore (down 30.9% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a standalone basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 189.75 | 145.07 | +30.8% | 276.53 | −31.4% |
| Other income | 2.65 | 2.67 | −1.0% | 3.48 | −23.9% |
| Total income | 192.40 | 147.75 | +30.2% | 280.01 | −31.3% |
| Profit before tax | 40.79 | 47.41 | −14.0% | 92.13 | −55.7% |
| Net profit for the period | 24.04 | 34.79 | −30.9% | 74.23 | −67.6% |
| EPS, basic (₹) | 2.99 | 4.32 | −30.8% | 9.22 | −67.6% |
| Net margin (%) | 12.7 | 24.0 | 26.8 |
Standalone
- Filed with BSE
- 13 Aug 2026, 18:58 IST
- Board meeting
- 13 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE